Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 436 | Poster Presentation | Rational Sequencing of Immune-Oncology Therapies Achieves Durable Response and Immunologic Memory | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell; Andrew Sharabi, MD, PhD, FACS; Joseph Califano; J. Silvio Gutkind; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Radiotherapy; Solid tumors; Surgery; T cell; Targeted therapy |
| 437 | Poster Presentation | Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC | Ann C. Anselme, BS; Wei Qian, BS; Roberto R. Rosato, PhD; Jianying Zhou; Jenny C. Chang, MD; Ann C. Anselme, BS; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 438 | Poster Presentation | Synergy Between SEA-CD40 and Chemotherapeutics Drives Curative Antitumor Activity in Preclinical Models | Weiping Zeng; Haley Neff-LaFord; Sahar Ansari; Celine Jacquemont, PhD; Michael Schmitt, MD, PhD; Shyra J. Gardai, PhD; | Combination Immunotherapies | Antibody; Antigen presenting cells; Chemotherapy; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 439 | Poster Presentation | Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity | Catherine A. Sabatos-Peyton, PhD; Tyler A. Longmire; Lisa Baker; Nidhi Patel; Anne-Sophie Wavreille; Melanie Verneret; Pushpa Jayaraman, PhD; Xiaomo Jiang; Stephanie Schwartz; Viviana Cremasco; Hongbo Lu; Shumei Qiu; Fiona A. Sharp, PhD; Mikael Rinne; Glenn Dranoff, MD; | Combination Immunotherapies | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| 440 | Poster Presentation | Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer | Guo Gui Sun; Jing Hao Jia; Peng Gao; Xue Min Yao; Ming Da Chen; Wei Nan Yao; Lu Sun; Wei Wang; | Combination Immunotherapies | COVID and Immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| 441 | Poster Presentation | Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized | Omar Alhalabi, MD; Elshad Hasanov; John Araujo; Jianbo Wang; Matthew T. Campbell, MD; Sangeeta Goswami, MD, PhD; Amishi Shah; Jianjun Gao, MD PhD; Pavlos Msaouel, MD, PhD; Nizar M. Tannir, MD, FACP; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Solid tumors |
| 442 | Poster Presentation | ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugué; Emmanuel Valentin, PhD; Jennifer Sims; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; Rene HOET; | Combination Immunotherapies | Antibody; T cell; T cell lineages |
| 443 | Poster Presentation | An Immunotherapy Trio in advanced HNSCC for coordinated B and T cell antigen response | Bernard A. Fox, PhD; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Noriko NI. Iwamoto, PhD; Christopher C. Paustian, PhD; Adi Mehta, PhD; Fridtjof Lund-Johansen, MD, PhD; Rachel E. Sanborn, MD; Bryan R. Bell, MD, DDS, FACS; Madeleine Laws, BS; Glenna McDonnell, MS; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Brian D. Piening, PhD; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Takashi Shimada, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Marcus A. Couey, MD, DDS; | Combination Immunotherapies | Antibody; Clinical study; Clinical trial; Costimulation; Neoantigens; Solid tumors; Surfaceome; T cell; Tumor antigens; Vaccine |
| 444 | Poster Presentation | MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination | Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Stephane Pourpe; Arnab Ghosh, MD, PhD; Cansu Cimen Bozkus, PhD; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; William Duke; Max Jan; Matthew J. Leventhal; Vincent Ho; Gabriela S. Hobbs; Trine Alma Knudsen; Vibe Skov; Lasse Kjær; Thomas Stauffer Larsen; Dennis Lund Hansen; R. Coleman Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, PhD; Morten O. Holmström; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD, PhD; Ann Mullally, M.D.; Taha Merghoub, PhD; Mathieu Gigoux, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor evasion; Vaccine |
| 445 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa | Lucas A. Horn, PhD; Linjie Tian, PhD; Dallas B. Flies, PhD; Linda N. Liu, PhD; Solomon Langermann, PhD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 446 | Oral Presentation | Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. | Peter I. Joyce, PhD; Lesley Young, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong; Kristopher Clark, PhD; Edd James, PhD; Emma Reeves, PhD; Alihussein Remtulla, PhD; Henry Leonard; Camila de Almeida; Elisa Lori; Nicola Ternette, PhD; Fergus Poynton, PhD; Andrew Leishman; | Combination Immunotherapies | Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 447 | Poster Presentation | VISTA targeting remodels the tumor microenvironment to overcome adaptive resistance | Janet L. Lines, Ph.D.; Evelien Schaafsma; Walburga Croteau; Mohamed ElTanbouly; Elizabeth Nowak; Nicole Smits; Cecilia A. Webber; Dina Rabadi; Jie Deng; Chao Cheng; Randolph Noelle; | Combination Immunotherapies | Gene expression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 448 | Poster Presentation | Discovery of clinical candidate IK-175, a selective orally active AHR antagonist | KAREN MCGOVERN, PhD; KAREN MCGOVERN, PhD; Alfredo C. Castro; Jill Cavanaugh; Marta Sanchez-Martin; Jeremy H. Tchaicha, PhD; Sakeena Syed; Hyejin Frosch; Prabitha Natarajan; Katie O'Callaghan; Ben Amidon, PhD; X. Michelle Zhang; Jeff Ecsedy; Mark Manfredi, PhD; | Combination Immunotherapies | Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 449 | Oral Presentation | Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation | Lauren Milling, BS; Darrell J. Irvine, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Surgery |
| 450 | Poster Presentation | Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice | Sujeong Park, graduate student; Ji-Hae Kim; Yeon-Woo Kang; Kun-Joo Lee; Dain Moon; Nara Tae; Yunji Park; Dae Hee Kim; Byung Ha Lee, PhD; Donghoon Choi, PhD; Se Hwan Yang, PhD; Seung-Woo Lee; | Combination Immunotherapies | Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 451 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D.; | Combination Immunotherapies | Cytokine; NK/NK T cell; Radiotherapy; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 452 | Poster Presentation | Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control | Matteo Rossi, PhD; Elodie Belnoue; Susanna Carboni; Wilma Besson-Di Berardino; Erika Riva; Marie-Laure Santiago-Raber; Madiha Derouazi; | Combination Immunotherapies | Immune adjuvant; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 453 | Poster Presentation | Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment | Jonas RM. Van Audenaerde, MSc; Elly Marcq; Bianca von Scheidt; Ashleigh S. Davey, PhD; Amanda J. Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y. Slaney; Marc Peeters, MD, PhD; Michael H. Kershaw, PhD; Phillip K. Darcy; Evelien LJ. Smits; | Combination Immunotherapies | Antibody; Antigen presenting cells; Cytokine; Dendritic cell; NK/NKT cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 454 | Poster Presentation | Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures | Namita Varudkar, MS, PhD Candidate; Namita Varudkar, MS, PhD Candidate; Jeremiah L. Oyer; Alicja Copik, PhD; Griffith Parks, PhD; | Combination Immunotherapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
| 455 | Oral Presentation | Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer | Sarmad Sadeghi, MD; Tyler D. Hether; Jason Yeon; Richard Mangio; Jason W. Reeves; Yan Liang, MD PhD; Sarah E. Warren, PhD; Troy McEachron, MD; Parkash S. Gill, MD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 456 | Poster Presentation | Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy | Julius Strauss, MD; Ravi A. Madan, MD; Marijo Bilusic, MD, PhD; Fatima Karzai; Scot Niglio; Jason M. Redman, MD; Houssein Abdul Sater, MD; Charalampos Floudas; Jung-Min Lee; Andrea B. Apolo, MD; Seth M. Steinberg; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 457 | Poster Presentation | Intratumoral interleukin-12 administered after cryoablation does not improve survival in multiple bilateral murine models | Maura R. Vrabel; Jake A. Schulman; David A. Zaharoff, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| 458 | Poster Presentation | Antitumor mechanisms of local radiation and combination immunotherapy in an immunologically cold model of neuroblastoma | Taylor Aiken, MD; Julie S. Voeller, MD; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | NK/NK T cell; Pediatric tumors; Radiotherapy; Regulatory T cell (Treg cell); Tumor microenvironment; Vaccine |
| 459 | Poster Presentation | NK cells activation and recruitment to irradiated tumors is increased in the presence of IL-15. | Maud Charpentier, PhD; Karsten A. Pilones, MD, PhD; Elena Garcia-Martinez, MD, PhD; Sandra Demaria, MD; | Combination Immunotherapies | NK/NKT cell; Radiotherapy |
| 460 | Poster Presentation | The immuno-metabolic enzyme FASN prevents anti-tumor immune responses in irradiated glioblastoma | Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD; | Combination Immunotherapies | Dendritic cell; Immune suppression; Metabolism; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 461 | Poster Presentation | Improving Specific Targeting of Tumors Through Bispecific SNIPER Antibodies | Amy K. Erbe, PhD; Daniel Gerhardt; Reinier Hernandez, PhD; Bonnie Hammer; Mildred A. Felder, BS; Mark Bercher; Jennifer Dennin; Christopher Massey; Sabrina VandenHeuvel; Arika S. Feils, BS; Mackenzie Heck; Jonathan Engle; Todd E. Barnhart; Jacquelyn A. Hank, PhD; Bryan Glaser, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Pediatric tumors; Radiotherapy |
| 462 | Poster Presentation | Single agent immunotherapy response in patients with head and neck squamous cell carcinoma with prior history of radiation therapy | Moises Harari-Turquie, MD; Shashank Cingam, MD; David Lee; Gregory Gan; Emrullah Yilmaz, MD, PhD; | Combination Immunotherapies | Chemotherapy; Epidemiology; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Tumor microenvironment |
| 463 | Poster Presentation | Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers | Maysaloun Merhi, PhD; Afsheen Raza; Varghese Inchakalody; Siveen Kodappully; Deepak Choubey; Fairooz Sahir; Sarra Mestiri; Shereena Hydrose; Niloofar Allahverdi; Munir D. Jalis; Allan Relecom; Lobna Al-Zaidan; Mohamed Sir Elkhatim Hamid; Mai Mostafa; Abdul Rehman Zar Gul; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermine; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| 464 | Poster Presentation | Clonal replacement of tumor-infiltrating CD8+ T cells by induction and activation of tumor-residing Batf3-dependent dendritic cells | Takaaki Oba, MD,PhD; Mark Long; Tibor Keler, PhD; Henry Marsh, BS PhD; Hans Minderman; Scott I. Abrams, PhD; Song Liu; Fumito Ito; | Combination Immunotherapies | Costimulation; Dendritic cell; Radiotherapy |
| 465 | Oral Presentation | Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection | Nils-Petter Rudqvist; Claire Lhuillier, PhD; Maud Charpentier, PhD; Erik Wennerberg, PhD; Sheila Spada, PhD; Caroline Sheridan; Xi Kathy Zhou; Tuo Zhang, PhD; Jennifer S. Sims, PhD; Alicia Alonso; Sandra Demaria, MD; | Combination Immunotherapies | Bioinformatics; Checkpoint blockade; Costimulation; Gene expression; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 467 | Poster Presentation | Anti-EGFR antibody added to ongoing anti-PD-1 antibody treatment for metastatic cutaneous squamous cell carcinoma of the face: two case reports | Omar Eton, MD, FACP; Emily Hsu, MD; Akshay V. Patel, DO; Omar Eton, MD, FACP; Richard Cartun, PhD; Jonathan S. Earle, MD; Laila O. Mnayer, PhD; Peter P. Yu, MD, FACP, FASCO; Jennifer Kotowitz, RN BSN; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors; Surgery; Targeted therapy; Tumor microenvironment |
| 468 | Poster Presentation | Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma | Sean E. Lawler, PhD; Marilin S. Koch, MD; Mikolay S. Zdioruk, phD; Estuardo Aguilar-Cordova; Laura K. Aguilar, MD, PhD; Brian W. Guzik; Ghazaleh Tabatabai; Michal Nowicki; E Antonio A. Chiocca; | Combination Immunotherapies | Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 469 | Poster Presentation | Cooperation between checkpoint inhibitors targeting the PD-1 / PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies | Amy Manning-Bog, PhD; Jeff DeFalco, PhD; Alexander Scholz, PhD; Iraz T. Aydin, PhD; Nikhil Vad, PhD; Cathrin Czupalla, Ph.D.; Felix Chu, MS; Mauricio Velasco-Delgado; Michael Harbell, M.S.; Judevin Lugar-Supagay; Yvonne Leung, Ph.D.; Shaun M. Lippow, Ph.D.; Anne Ye, PhD; Ish Dhawan, PhD; Gilson Baia, PhD; Dai-Chen Wu, PhD; Carl Millward, MD; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; John Vivian, PhD; Ngan Nguyen, BS PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 470 | Oral Presentation | Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors | Jeff S. Miller, MD; Nicholas A. Zorko, MD, PhD; Behiye Kodal; Zachary B. Davis, PhD; Alexander J. Lenvik; Todd R. Lenvik; Joshua S. Walker; Daniel A. Vallera; Svetlana Gaidarova, MS; Alejandro Garcia; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Frank S. Cichocki, PhD; Martin S. Felices; | Combination Immunotherapies | Adoptive immunotherapy; Bispecifics; NK/NK T cell |
| 471 | Poster Presentation | Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition | Francesco Novelli, PhD; Claudia Curcio, PhD; Cecilia Roux; Laura Conti; Roberta Curto; Gianluca Mucciolo; Sara Bulfamante, MS; Silvia Brugiapaglia; Alessandro Scagliotti; Alessandra Ghigo; Paola Cappello, PhD MS; Emilio Hirsch; Francesco Novelli, PhD; | Combination Immunotherapies | Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| 472 | Oral Presentation | ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma | Natasha D. Sheybani, PhD; Soumen Paul, PhD; Katelyenn S. McCauley; Victoria R. Breza; Stuart S. Berr, PhD; G. Wilson Miller, PhD; Kiel D. Neumann, PhD; Richard J. Price, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Solid tumors; Targeted therapy |
| 473 | Poster Presentation | Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro. | Luis A. Carvajal, PhD.; Luciana Gneo, PhD.; Carmela De Santo, PhD; Matt Perez, B.S; Tracy Garron, B.S; Francis Mussai, M.D; Annalisa D’Andrea, PhD.; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 474 | Poster Presentation | Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: one institutional experience in Taiwan since 2016 | Jo-Pai Chen, MD; Wei-Chen Lu, M. D.; Ruey-Long Hong, M.D. PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| 814 | Poster Presentation | MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity. | Kees Bol, PhD; Wilfred Marissen, PhD; Jeroen Elaissais-Schaap, PhD; Paul J. Tacken, PhD; Steef Engels; Liang-chuan Wang, PhD; Arpita Mondal; Mark Throsby, PhD; Alan Roberts, PhD; Patrick Mayes, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Costimulation; Immune suppression; Immune toxicity; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 816 | Poster Presentation | Evaluating the potential of harnessing anti-leukemia T cells for the treatment of T cell Acute Lymphoblastic Leukemias (T-ALL) | Todd A. Triplett, PhD; Sarah E. Church, PhD; Tyler D. Hether; Joshua F. Rios; Srividya Kottapalli; Nisha Holay, B.S.; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Leukemia/Lymphoma; Pediatric tumors; T cell; T cell lineages; Tumor microenvironment; Tumor stroma |
| 817 | Poster Presentation | DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties | Anne-Laure Blayo; Laurène Deshons; Alexia Dumont; Christel Franchet; Célia Halter; Ludovic Herbin; Gaël Hommet; Stanislas Mayer; Alban Bessede; Imane Nafia; Marjorie Sidhoum; Xavier Leroy; Stéphan Schann; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Tumor microenvironment |
| 818 | Poster Presentation | Synergistic cancer immunotherapy using tumor tissue-derived exosomes and artificially produced bacterial outer membrane vesicles | Kyong-su Park, PhD; Jan Lötvall; Kristina Svennerholm; Rossella Crescitelli; Cecilia Lässer; Inta Gribonika; | Combination Immunotherapies | Extracellular vesicles/exosomes; Cytokine; Dendritic cell; Inflammation; Neoantigens; T cell; Tumor antigens; Vaccine |
| 819 | Poster Presentation | Targeting vasoactive intestinal peptide receptor signaling: A novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD, MS; Passang Tenzin; Sanjay Chandrasekaran, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Shuhua Wang, MD; Rohan K. Dhamsania, BS; Jingru Zhu; Susan N. Thomas, PhD, BS; Anish Majumdar,; Gregory B. Lesinski, PhD; Bassel El-rayes, MD; Edmund K. Waller, MD, PhD; | Combination Immunotherapies | Solid tumors |
| 820 | Poster Presentation | MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells | Paul J. Tacken, PhD; Liang-chuan Wang, PhD; Rinse Klooster; Pieter Fokko Van Loo, PhD; Jing Zhou, MD, PhD; Arpita Mondal; Yao-Bin Liu; Arjen Kramer; Thomas Condamine, PhD; Alla Volgina; Linda Hendriks; Hans van der Maaden; Eric Rovers; Steef Engels; Floris Fransen; Renate den Blanken-Smit; Vanessa Zondag-van der Zande; Abdul Basmeleh; Willem Bartelink; Ashwini Kulkarni; Wilfred Marissen, PhD; Cheng-Yen Huang; Leslie Hall; Shane Harvey; Chrysi Kanellopoulou, PhD; Shaun Stewart; Horacio Nastri; Lex Bakker, PhD; Ton Logtenberg; Simon Plyte; Patrick Mayes, PhD; Mark Throsby, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Coinhibition; Costimulation; Immune adjuvant; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 821 | Poster Presentation | Class specific HDAC inhibition differentially affects the function of specific T cell subsets | Nisha Holay, B.S.; Uma Giri, Ph.D.; Carla Van Den Berg, Pharm.D.; Gail Eckhardt, MD; Todd A. Triplett, PhD; | Combination Immunotherapies | Post-translational modifications; Epigenetics; Cytokine; T cell; T cell lineages |
| 822 | Poster Presentation | Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer | Marco Catucci; Veronica Basso; Chiara Lucrezia Deantoni; Simone Baroni; Antonello Spinelli; Massimo Freschi; Cesare Cozzarini; Claudio Fiorino; Nadia Di Muzio; Silvia C. Formenti, MD; Sandra Demaria, MD; Anna Mondino; | Combination Immunotherapies | Adoptive immunotherapy; Radiotherapy; Solid tumors |
| 823 | Poster Presentation | CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model | Arika S. Feils, BS; Mackenzie Heck; Anna Hoefges, MS; Peter M. Carlson, BS; Luke Zangl; Ravi Patel, MD, PhD; Dmitriy Kravtsov; Jacquelyn A. Hank, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Amy K. Erbe, PhD; | Combination Immunotherapies | Radiotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 824 | Poster Presentation | Modulation of TLR3 protein in response to radiation in squamous cell lung carcinoma | Jeru M. Manuel, PhD; Ebru Tas, B.Sc; Cleopatra Rutihinda, B.Sc; Ayman J. Oweida, PhD; | Combination Immunotherapies | Gene expression; Radiotherapy; TLR; Tumor microenvironment |
